Skip to main content

Recent Drug Approvals for Blood Cancer Mark Significant Progress for Patients

By Lee Greenberger, PhD, Chief Scientific Officer, LLS | April 19, 2020

Driving forward science

While we all are navigating uncertainty and challenges in these unprecedented times, there is promising news: science is racing forward. Dedicated researchers around the world are collaborating in new ways, sharing data openly and advancing our understanding of the novel virus that causes coronavirus disease (COVID-19). In fact, more than 70 countries have joined the World Health Organization in accelerating research on effective treatments for COVID-19 and about 20 institutions and companies are pushing to develop a vaccine. What’s more, numerous drugs initially approved by the U.S. Food and Drug Administration (FDA) to treat blood cancers are now being explored to control the hyperimmune response to COVID-19. LLS-funded researchers are bringing these COVID-19 trials to the forefront. You can read some of the latest scientific papers on COVID-19 here.

LLS remains as committed as ever to our mission – including staying the course with our investment in cutting edge blood cancer research around the globe. We’re proud to support our global community of pioneering researchers who are adapting and innovating in this new normal. To inspire blood cancer patients, families, researchers, healthcare professionals, volunteers and supporters everywhere, I’d like to reflect on how far we’ve come in treating blood cancers in the past three years alone, thanks to the tireless work of LLS-funded researchers who are relentless for cures.